Logo image of MTVA

METAVIA INC (MTVA) Stock Fundamental Analysis

NASDAQ:MTVA - Nasdaq - US64132R4048 - Common Stock - Currency: USD

0.6346  -0.03 (-4.36%)

After market: 0.6472 +0.01 (+1.99%)

Fundamental Rating

1

Overall MTVA gets a fundamental rating of 1 out of 10. We evaluated MTVA against 553 industry peers in the Biotechnology industry. MTVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MTVA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MTVA has reported negative net income.
MTVA had a negative operating cash flow in the past year.
In the past 5 years MTVA always reported negative net income.
In the past 5 years MTVA always reported negative operating cash flow.
MTVA Yearly Net Income VS EBIT VS OCF VS FCFMTVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

MTVA's Return On Assets of -202.43% is on the low side compared to the rest of the industry. MTVA is outperformed by 88.97% of its industry peers.
MTVA's Return On Equity of -560.48% is on the low side compared to the rest of the industry. MTVA is outperformed by 78.84% of its industry peers.
Industry RankSector Rank
ROA -202.43%
ROE -560.48%
ROIC N/A
ROA(3y)-88.7%
ROA(5y)-125.52%
ROE(3y)-162.29%
ROE(5y)-200.75%
ROIC(3y)N/A
ROIC(5y)N/A
MTVA Yearly ROA, ROE, ROICMTVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MTVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTVA Yearly Profit, Operating, Gross MarginsMTVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MTVA has more shares outstanding
Compared to 5 years ago, MTVA has more shares outstanding
MTVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MTVA Yearly Shares OutstandingMTVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MTVA Yearly Total Debt VS Total AssetsMTVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

MTVA has an Altman-Z score of -21.70. This is a bad value and indicates that MTVA is not financially healthy and even has some risk of bankruptcy.
MTVA's Altman-Z score of -21.70 is on the low side compared to the rest of the industry. MTVA is outperformed by 85.71% of its industry peers.
MTVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.7
ROIC/WACCN/A
WACCN/A
MTVA Yearly LT Debt VS Equity VS FCFMTVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.55 indicates that MTVA should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.55, MTVA is doing worse than 80.65% of the companies in the same industry.
A Quick Ratio of 1.55 indicates that MTVA should not have too much problems paying its short term obligations.
MTVA has a worse Quick ratio (1.55) than 80.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.55
MTVA Yearly Current Assets VS Current LiabilitesMTVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

MTVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.14%, which is quite impressive.
EPS 1Y (TTM)27.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MTVA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.04% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y65.26%
EPS Next 2Y29.33%
EPS Next 3Y15.99%
EPS Next 5Y-1.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTVA Yearly Revenue VS EstimatesMTVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 50M 100M 150M 200M 250M
MTVA Yearly EPS VS EstimatesMTVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 -5K -10K -15K -20K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MTVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MTVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTVA Price Earnings VS Forward Price EarningsMTVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTVA Per share dataMTVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

MTVA's earnings are expected to grow with 15.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.33%
EPS Next 3Y15.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MTVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METAVIA INC

NASDAQ:MTVA (7/29/2025, 5:20:00 PM)

After market: 0.6472 +0.01 (+1.99%)

0.6346

-0.03 (-4.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-19 2025-08-19
Inst Owners3.65%
Inst Owner ChangeN/A
Ins Owners0.59%
Ins Owner Change1.71%
Market Cap12.43M
Analysts84.44
Price Target14.03 (2110.84%)
Short Float %1.3%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.24%
Min EPS beat(2)27.07%
Max EPS beat(2)41.42%
EPS beat(4)3
Avg EPS beat(4)8.29%
Min EPS beat(4)-61.46%
Max EPS beat(4)41.42%
EPS beat(8)6
Avg EPS beat(8)1.84%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.29%
EPS NQ rev (1m)17.7%
EPS NQ rev (3m)31.87%
EPS NY rev (1m)8.84%
EPS NY rev (3m)26.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.84
P/tB 2.84
EV/EBITDA N/A
EPS(TTM)-3.26
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -202.43%
ROE -560.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.7%
ROA(5y)-125.52%
ROE(3y)-162.29%
ROE(5y)-200.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.55
Altman-Z -21.7
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)291.11%
Cap/Depr(5y)174.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
EPS Next Y65.26%
EPS Next 2Y29.33%
EPS Next 3Y15.99%
EPS Next 5Y-1.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-144.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-144.78%
OCF growth 3YN/A
OCF growth 5YN/A